Physician profile
Casey Worsham
NPI 1437605250
$1,490.99
in general payments reported to CMS, 2019-2025
18 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $289 · 2023: $280 · 2024: $576 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.22 | 2021-2025 | |
| Novo Nordisk INC | $217.03 | 2022-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $161.21 | 2021-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.70 | 2021-2024 | Xifaxan |
| Amgen INC. | $96.55 | 2021-2023 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $92.64 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $78.39 | 2021-2022 | |
| Glaxosmithkline, LLC. | $58.09 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $42.59 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $39.77 | 2021 | |
| Insulet Corporation | $33.12 | 2024 | Omnipod |
| Mylan Specialty L.P. | $33.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.25 | 2021-2024 | Breztri |
| Idorsia Pharmaceuticals US INC | $29.96 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $29.12 | 2023-2024 | Vaxneuvance, M-M-R II, Gardasil 9 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $19.95 | 2024 | |
| Abbott Laboratories | $19.19 | 2024 | Proclaim |
| Otsuka America Pharmaceutical, INC. | $16.12 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Worsham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.